MPO and crescentic glomerulonephritis: More pointedly, early clinical trials of aminoguanidine to prevent microvascular disease in patients with diabetes were complicated by several cases of overt MPO antibody associated ANCA vasculitis, which presented as crescentic glomerulonephritis (28).